Douglas J. Williamson - 14 Feb 2022 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Chief Medical Officer
Signature
/s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
14 Feb 2022
Transactions value $
$0
Form type
4
Filing time
16 Feb 2022, 15:40:17
Next filing
13 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +275K $0.00 275K 14 Feb 2022 ADSs 275K $6.60 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options become exercisable as to 68,750 ADSs on each of the first four anniversaries after the 2/14/2022 grant date.
F2 The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.